Survival Outcomes of Neoadjuvant mFOLFIRINOX for Resectable PDAC

Michael Cecchini, MD, highlights his latest research evaluating the efficacy of neoadjuvant mFOLFIRINOX in improving survival and controlling micrometastasis in resectable pancreatic ductal adenocarcinoma.

Dr. Cecchini also discusses how circulating tumor DNA was used in this study as well as which methods were used for collecting and analyzing ctDNA levels.

0:00 Investigation Motivations

2:26 Study Design and Methodology

4:31 Correlation of Baseline ctDNA Levels With Patient Outcomes

6:30 OS and PFS

9:43 Further Research Needs

11:48 Final Thoughts